Navigation Links
BCM-95 Demonstrates Superior Anti-Inflammatory Effects

GREEN BAY, Wis., Sept. 16 /PRNewswire/ -- Top researchers at the Gastrointestinal Cancer Research Lab at Baylor University Medical Center in Dallas are exploring the clinical applications of BCM-95®, a new patented extract of curcumin with unprecedented potency, and bioavailability.

Previous studies have shown that BCM-95 curcumin was 7-10 times more bioavailable than other forms of curcumin, and had a retention time in the bloodstream between 8 to 12 hours.(1) At all points in the study, BCM-95 curcumin levels were higher than any other form of curcumin tested. This superior absorption and retention is attained by a patented process that involves homogenization and micronization with turmeric essential oil which is then bound to natural plant phospholipids.

"We have the most fascinating and convincing scientific laboratory evidence from thousands of  studies finding that curcumin has potent anti-inflammatory properties," said Ajay Goel, Ph.D., Investigator at the Gastrointestinal Cancer Research Lab at Baylor University. "Abundant data point to the pain-relieving and anti-inflammatory efficacy of curcumin – and these benefits are essentially drawn from its ability to suppress and inhibit the activities of two major pro-inflammatory targets within our cells: NF-kB and COX-2." Dr. Goel's  group was the first to demonstrate that curcumin acts as a specific COX-2 inhibitor, and hence, plays an important role in not only alleviating everyday pain, but has the potential to prevent many chronic diseases that manifest themselves in the background of increased inflammation.

While curcumin holds huge promise as an anti-inflammatory, pain relieving substance, in the human body curcumin is poorly absorbed.  "However, BCM-95 amplifies and potentiates its effectiveness," Dr. Goel explained. "Not only is BCM-95 curcumin absorbed up to 10 times better than conventional curcumin, it also is retained in the body longer. Currently, we have several scientific studies underway in our laboratory on BCM-95, and we are extremely encouraged by the new promising discoveries we are making with this miracle herb."

According to Dr. Goel, inflammation is a factor in 80-90% of all disease. Curcumin demonstrates superior antioxidant and anti-inflammatory effects, and provides liver and heart-protective benefits as well. It is a potent anti-bacterial, anti-fungal, anti-viral, anti-allergenic, and has anti-tumor and anti-cancer properties.

EuroPharma, Inc. is the exclusive distributor of BCM-95® in the U.S. through both the health food store and professional distribution channels. EuroPharma offers clinically proven and effective nutritional supplements and natural remedies that improve the health of America. At EuroPharma, Our Passion is Your Health®. For more information on EuroPharma, visit

(1) Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyala S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (Biocurcumax) a novel bioenhanced preparation of curcumin. Ind J Pharm Sci. 2008. 2008;70(4):445-450.

SOURCE EuroPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EuroPharma Exclusive Distributor of BCM-95 and BosPure
2. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
7. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
8. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... GKhair & Tibolli ... the San Juan Beauty Show held on November 8th and 9th at the Puerto ... media personalities, hair artists, renowned beauticians and top of the line fashion journalists. The ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today that ... Program with competencies in the Application Development, demonstrating a “best-in-class” ability and ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... product dealer. Joining more than 30 HealthPostures’ dealers located throughout the United States, ... increase the number of corporate, industrial, manufacturing and government workers and organizational leaders ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... patented products, announces the Unstoppable Swappables, a household invention that provides an economical ... $2 billion a year and is growing at 2.6%," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):